Breast Cancer

Will the FDA approve giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy?

Martha Welman, MD, discusses the value of personalized patient relationships over technology, especially for populations with limited access to resources.

At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.

Martha Welman, MD, discusses several personalized health care disparity interventions that have been shown to increase access to breast cancer screening.

Martha Welman, MD, discusses findings from a study of strategic screening initiatives aimed at reducing breast cancer diagnostic disparities.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

Martha Welman, MD, discusses patient navigation interventions aiming to address unmet needs in the breast cancer screening and diagnosis pathway.

David Rimm, MD, PhD, discusses whether ADCs should be considered similar to targeted therapy, or whether this class of agents is more akin to chemotherapy.

The FDA has issued REMS safety updates regarding the use of the denosumab biosimilars Enoby and Ospomyv for patients with breast and prostate cancers.

Dr Bardia discusses key findings from the phase 3 lidERA Breast Cancer study of giredestrant in estrogen receptor–positive, HER2-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

David Rimm, MD, PhD, discusses the strategic sequencing of ADCs in breast cancer, asserting that these agents should be classified as targeted therapies.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

The NCCN guidelines recognize that MammaPrint can help identify a subset of patients with early-stage breast cancer likely to benefit from anthracycline-based therapy.